Introduction {#Sec1}
============

Although dietary fat has been implicated in the etiology of colorectal cancer \[[@CR1]\], results from epidemiological studies are inconsistent \[[@CR2], [@CR3]\] and often do not support an association, as observed recently in the Women's Health Study \[[@CR4]\]. Fortunately, current molecular techniques to detect DNA alterations on a large scale allow studying molecular endpoints for colorectal cancer, characterized by acquired (epi) genetic defects in tumor DNA \[[@CR5]\]. This approach may improve our ability to observe associations between dietary factors and cancer that may otherwise remain undetected.

A multistep model linking sporadic colorectal carcinogenesis to molecular aberrations has been proposed \[[@CR6]--[@CR8]\], with DNA repair genes, tumor suppressor genes and oncogenes, operating in multiple genetic pathways. About 10--20% of sporadic colon carcinomas are characterized by microsatellite instability, predominantly due to promoter methylation of the MLH1 (mutL homolog 1, colon cancer, nonpolyposis type 2) DNA mismatch repair gene, which prevents expression of the enzyme \[[@CR9]\]. Up to 90% of colon and rectum carcinomas are chromosomally instable \[[@CR10], [@CR11]\] and are associated with mutations in the *APC* (adenomatous polyposis coli) and *TP53* (tumor protein 53) tumor suppressor genes and in the *KRAS* (v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) oncogene \[[@CR12]\]. However, simultaneous occurrence of mutations in these three genes is rare suggesting that, even within this group of chromosomally instable tumors, different genetic pathways to colorectal cancer exist \[[@CR13], [@CR14]\]. Mutations in the *APC* gene are found to occur relatively early in colorectal tumorigenesis and are observed in up to 80% of both adenomas and carcinomas \[[@CR8], [@CR15]\]. Mutations in the *KRAS* gene are observed in approximately 10--20% of small adenomas and 40--50% of larger adenomas and carcinomas, suggesting it to be an important event in the progression of adenoma to carcinoma \[[@CR15]\]. Mutations in the *TP53* gene are postulated to affect relatively late stages of colorectal carcinogenesis \[[@CR15]\].

Breivik et al. proposed that the type of genetic instability in cancer cells reflects the selection pressures exerted by specific carcinogens \[[@CR16]\]. Bardelli et al. subsequently tested this hypothesis in immortal genetically stable human cells and concluded that exposure to specific carcinogens can indeed select for tumor cells with distinct forms of genetic instability and *vice versa* \[[@CR17]\]. Therefore, DNA adducts derived from dietary fat metabolism could also be associated with colorectal tumors exhibiting chromosomal instability. This is supported by the observations that malondialdehyde (MDA), generated during lipid peroxidation and arachidonic acid metabolism, can form DNA adducts and induce G→T transversions and G→A transitions in DNA \[[@CR18], [@CR19]\]. In addition, higher levels of MDA-DNA adducts have been observed in colorectal tissue of adenoma patients than in tissue of controls \[[@CR20]\]. MDA levels are modulated by dietary factors, with polyunsaturated fatty acids, and specifically ω-6 polyunsaturated fatty acids, presumably increasing MDA levels \[[@CR21]\]. This is in line with our previous report of a significant association between the intake of linoleic acid, the most abundant ω-6 polyunsaturated fatty acid in the diet, and increased risk of colon carcinomas with a mutated *KRAS* gene within the Netherlands Cohort Study (NLCS) on diet and cancer \[[@CR22]\].

These observations and hypotheses prompted us to investigate the associations between the intake of total fat and different types of fat and the risk of colon and rectal tumors lacking MLH1 expression and with and without *APC* gene mutations, two early events in colorectal tumorigenesis, independent of tumors harboring *KRAS* gene mutations.

Materials and methods {#Sec2}
=====================

Study population {#Sec3}
----------------

The prospective NLCS was initiated in The Netherlands in September 1986. The study design has been described in detail elsewhere \[[@CR23]\]. Briefly, at baseline a total of 58,279 men and 62,573 women, between the ages of 55 and 69 years, completed a self-administered food frequency and lifestyle questionnaire. Incident cancer cases are identified by monitoring of the entire cohort for cancer occurrence through annual record linkage to the National Cancer Registry (NCR), consisting of nine regional cancer registries throughout The Netherlands, and to PALGA, a nationwide network and registry of histo- and cytopathology \[[@CR24]\]. The NCR and PALGA together provide a near 100% coverage of the 204 municipalities included in the NLCS.

Accumulation of person-time in the cohort was estimated through biennial vital status follow-up of a subcohort of 3,500 men and women who were randomly selected after baseline exposure measurement \[[@CR24]\]. Cases with prevalent cancer other than non-melanoma skin cancer were excluded from the subcohort, which left 3,346 men and women for analysis next to all colorectal cancer cases from the entire cohort. No subcohort members were lost to follow-up. A flow diagram of subcohort members and patients on whom the analyses are based is given in Fig. [1](#Fig1){ref-type="fig"}. Fig. 1Flow diagram of the number of subjects on whom the final statistical analyses were based. ^a^Netherlands Cancer Registry. ^b^Pathologisch Anatomisch Landelijk Geautomatiseerd Archief. ^c^Patients with rectosigmoid tumors were not included in the analyses. ^d^mutL homolog 1, colon cancer, nonpolyposis type 2. ^e^Adenomatous polyposis coli. ^f^Mutation cluster region. ^g^v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog. ^h^Patients with rectal tumors were not included in the analysis according to MLH1 expression

The first 2.3 years of follow up were excluded because of possible preclinical disease affecting exposure status and because of incomplete nationwide coverage of PALGA alone (i.e., not in combination with the NCR) in some of the municipalities included in the NLCS. Within this period, 83 subcohort members deceased or were diagnosed with cancer other than non-melanoma skin cancer, leaving 3,263 subcohort members for analysis. From 1989 to 1994, 929 incident cases with histologically confirmed colorectal cancer were identified within the entire cohort, of whom 819 could also be linked to a PALGA report of the lesion. The PALGA reports were used to identify and locate tumor tissues from eligible colorectal cancer patients in 54 pathology laboratories throughout the Netherlands. Cancers were classified according to site as follows, colon: cecum through sigmoid colon (ICD-O codes 153:0, 153.1, 153.2, 153.3, 153.4, 153.5, 153.6, 153.7), proximal colon (ICD-O codes 153.0, 153.1, 153.4, 153.5, 153.6), distal colon (ICD-O codes 153.2, 153,3, \`53.7), rectosigmoid (ICD-O code 154.0), and rectum (ICD-O code 154.1).

Tissue samples {#Sec4}
--------------

Approval for collection of archival tissue samples from colorectal cancer patients was obtained from the Ethical Review Board of University Maastricht, the NCR and PALGA. The tissue specimen collection started in August 1999 and was completed in December of 2001. For five percent of patients, tissue samples could not be retrieved (44/819) due to administrative inconsistencies. Of 775 available tissue samples, 737 (95%) contained sufficient tumor material for molecular analyses of MLH1 expression and mutations in *APC* and *KRAS* genes.

Since the rectosigmoid can be considered as a clinically applied term rather than an anatomically defined transitional zone between the colon and rectum, the 85 patients with a rectosigmoid tumor were excluded from data analysis. Moreover, the group of patients with a rectosigmoid tumor was too small for adequate stratified analysis.

MLH1 expression analysis {#Sec5}
------------------------

Formalin-fixed, paraffin-embedded tissues were sectioned at 4 μm and contained tumor tissue and normal adjacent mucosa. Endogeneous peroxidase activity was blocked with 3% H~2~O~2~. Slides were submitted to microwave antigen retrieval in 1mM EDTA buffer (pH 8.0) and incubated with 10% normal horse serum for 10 min at room temperature. Then, sections were incubated overnight at 4°C with mouse monoclonal antibodies against MLH1 protein (clone G168--15, PharMingen, San Diego, CA) at a 1:100 dilution. Antibody binding was detected by incubating the sections at room temperature with the peroxidase-labeled DAKO Envision System (DAKO, Carpinteris, CA) and using DAB as a chromogen. Sections were counterstained with haematoxylin.

Lesions were considered to lack MLH1 protein expression when unequivocal absence of nuclear staining of the tumor epithelial cells was observed. Nuclear staining of normal epithelial and stromal cells or lymphocytes served as internal positive control. Two investigators reviewed the immunohistochemical staining independently and discrepancies were re-examined and discussed with a pathologist until consensus was reached. MLH1 expression status was determined successfully in 98% of samples, i.e., 468 colon tumors and 173 rectum tumors (Fig. [1](#Fig1){ref-type="fig"}).

*APC* mutation analysis {#Sec6}
-----------------------

The majority of somatic mutations in *APC* occur within the mutation cluster region. Mutation analysis of the mutation cluster region (codons 1,286--1,520), was performed on archival adenocarcinoma specimens, using macrodissection followed by extraction of tumor DNA. Then nested PCR was used to amplify the mutation cluster region in four overlapping DNA fragments and the purified fragments were sequenced. This procedure has been described in detail elsewhere \[[@CR25]\]. In brief, in a first round of PCR, two overlapping fragments were generated, that served as templates for a second round of PCR to amplify four overlapping biotin-labeled PCR fragments that were subsequently used for direct sequencing. The sequence profile was analyzed on ALFexpress DNA Analysis System using ALFwin software (Amersham Biosciences, Roosendaal, The Netherlands). Evaluation of the sequence patterns and data entry were independently performed by two observers. Sensitivity and specificity was assessed by analyzing the mutational status of *APC* in six colorectal cancer cell lines. Both sensitivity and specificity were regarded to be satisfactory since specific mutations in the mutation cluster region of *APC* were confirmed in CaCo2 cells, SW480 cells and LOVO cells, as previously described \[[@CR25], [@CR26]\], and wild type sequences were confirmed in HCT116, Colo205 and HT29, for the mutation cluster region of *APC*\[[@CR25]\]. In addition, the detection limit was 5% of mutated DNA \[[@CR25]\]. Reproducibility of mutation analysis was regarded to be satisfactory since 85% of duplicate analyses, from flank PCR of genomic DNA to sequencing of the four fragments (i.e., 61 out of 72 fragments), revealed identical mutation status of *APC* \[[@CR25]\].

From 47 colon cancer patients and 25 rectum cancer patients, one or more fragments of the *APC* gene mutation cluster region could not be amplified and these patients were not included in this study, leaving 429 colon and 151 rectum cancer cases with successful analysis of the mutation cluster region of the *APC* gene (Fig. [1](#Fig1){ref-type="fig"}).

*KRAS* mutation analysis {#Sec7}
------------------------

Mutation analysis of the exon1 fragment of the *KRAS* oncogene, spanning codons 8--29, was performed on archival adenocarcinoma specimens, using nested PCR, followed by direct sequencing of purified fragments \[[@CR27]\]. The detection limit was 5% mutated DNA. Reproducibility was regarded to be satisfactory, since 88% of duplicate analyses, from tissue sectioning to DNA sequencing (i.e., 28 out of 32), revealed identical mutation status of *KRAS* \[[@CR27]\]. Mutation analysis was performed with success on 476 colon and 176 rectum cancer cases (Fig. [1](#Fig1){ref-type="fig"}).

Exposure assessment {#Sec8}
-------------------

The 150--item semi-quantitative food frequency questionnaire concentrated on habitual consumption of food and beverages during the year preceding the start of the study. Mean individual nutrient intakes per day were computed using the computerized Dutch food composition table of 1986 \[[@CR28]\]. The questionnaire was validated against a 9-day diet record \[[@CR29]\]. Crude and energy-gender-adjusted (in parentheses) correlation coefficients were 0.72 (0.52) for total fat, 0.73 (0.58) for saturated fat and 0.73 (0.75) for polyunsaturated fat \[[@CR29]\]. For energy intake the correlation coefficient was 0.74. On average, the questionnaire covered 91% of the energy intake assessed by the record intake. Questionnaire data were key-entered twice and processed for all incident cases in the cohort and for all subcohort members in a manner blinded with respect to case/subcohort status.

For 7% of subjects (either cases or subcohort members), dietary data were incomplete or inconsistent, and they were excluded from the analyses. Questionnaires were considered incomplete when either: (1) more than 60 items were left blank and less than 35 items were eaten at least once a month; or (2) one or more item blocks (groups of items, e.g., beverages) were left blank. Additional details are given elsewhere \[[@CR29]\]. This resulted in the availability of 3,048 subcohort members, 441 colon cancer cases for whom MLH1 expression status was known, and 414 colon and 136 rectal cancer cases for whom *APC* and *KRAS* mutation status was known. No data-analyses were conducted for lack of MLH1 expression in rectal cancer cases since there were only two such cases in the cohort (Fig. [1](#Fig1){ref-type="fig"}).

Intake of specific fatty acids was based on a food composition database with specific fatty acids derived from the TRANSFAIR study \[[@CR30]\]. For this database, the hundred foods that contributed most to fat intake in the Dutch dietary pattern were sampled and analyzed as methyl esters of the fatty acids present in the foods. In the database, total fat includes triglycerides and other lipids such as phospholipids and sterols. The percentage of triglycerides in total fat is assumed to be 93% on average, but varies across food sources. Daily intakes of total fat (g/day), saturated fat (g/day), monounsaturated fat (g/day), polyunsaturated fat (g/day), and linoleic acid (C18:2, C9, 12) (g/day) and linolenic acid (C18:3, C9, 12, 15) (g/day) as the main constituents of polyunsaturated fat, were used as exposure variables. Linoleic and linolenic acid were used as the most abundant sources of ω-6 polyunsaturated fatty acids and ω-3 polyunsaturated fatty acids in the diet. In all analyses, the values for fat intake variables are adjusted for energy intake by the residual method \[[@CR31]\]. For data analyses, quartiles of the intake of fat and different types of fats were computed based on the distribution of subcohort members. Daily intake of dietary fiber (g/day), alcohol (g/day), fruit (g/day), vegetables (g/day) and total energy (kJ/day) and age at baseline (years), sex (men/women), body mass index (kg/m^2^), non-occupational physical activity (\<30 min/day, 30--60 min/day, 60--90 min/day, \>90 min/day), family history of colorectal cancer (yes/no) and smoking status (never/ex/current) were regarded as potential confounders.

Statistical analysis {#Sec9}
--------------------

Data analyses were based on study participants for whom data on fat intake and confounding variables were complete, i.e., 2,948 subcohort members, 428 colon cancer patients for whom MLH1 expression status was known, and 401 colon cancer and 130 rectal cancer patients for whom *APC* and *KRAS* mutation status was known (Fig. [1](#Fig1){ref-type="fig"}).

Data analyses were conducted separately for overall colon and rectal cancer, colon cancer lacking MLH1 expression, colon and rectal cancer with or without a truncating *APC* mutation, described here as *APC*^+^ and *APC*^−^tumors respectively. Truncating *APC* mutations lead to the introduction of a stop codon and result in a truncated and therefore, inactive *APC* protein. The analyses with truncating *APC* mutations were also conducted separately for the most common point mutations resulting in the introduction of a stop codon, i.e., C:G → T:A or G:C → T:A point mutations. As indicated previously, associations between fat intake and *KRAS* mutated tumors have been described in this population previously, and a positive association between the intake of linoleic acid and *KRAS* mutated colon tumors was observed \[[@CR22]\]. Therefore, when (borderline) significant associations were observed with any of the colon tumor endpoints, analyses were repeated excluding tumors harboring mutations in *KRAS*.

Since tumors may harbor multiple mutations it is difficult to assess whether observed associations are specific for tumors with a particular gene defect. We therefore, conducted additional analyses when (borderline) significant associations were observed. In these analyses subgroups of tumors were formed characterized by either the absence of the three gene defects, or by defects in a single gene, i.e., either only lack of MLH1 expression, only a truncating *APC* mutation or only an activating *KRAS* mutations. Activating *KRAS* mutations are defined as mutations in codons 12 and 13 of the *KRAS* gene leading to an altered amino acid.

Mean values of the intake of fat variables (g/day), and possible confounding variables including age at baseline (years), dietary fiber (g/day), alcohol (g/day), intake of fruit (g/day), vegetable (g/day), energy (kJ/day), and BMI (kg/m^2^), as well as distributions of the variables sex, family history of colorectal cancer (yes/no), smoking status (never/ex/current smoker) and physical activity in leisure time (\<30, 30--60, 60--90, \>90 min/day) were evaluated for subcohort members, colon and rectal cancer patients with or without a truncating *APC* mutation and colon cancer patients lacking MLH1 expression. Differences in mean values of the continuous variables between patients with or without truncating nonsense or frameshift mutations in the mutation cluster region of the *APC* gene, and between patients with or without MLH1 expression, were tested using the Mann--Whitney-*U*-test since the variables were not normally distributed among cases. The distributions of the categorical variables between patients with and without truncating *APC* mutations were tested with the χ^2^--test.

Incidence rate ratios (RR) and corresponding 95% confidence intervals (CI) for colon and rectal cancer patients were estimated according to quartiles of intake of fat variables, and one standard deviation increment of intake, using Cox proportional hazards regression models. In addition, associations were estimated for specific molecular endpoints of the tumors.

Standard errors were estimated using the robust Huber--White sandwich estimator to account for additional variance introduced by sampling the subcohort from the entire cohort \[[@CR32], [@CR33]\]. The proportional hazards assumption was tested using the scaled Schoenfeld residuals \[[@CR34]\]. Tests for dose response trends over the different quartiles and categories of fat intake were estimated by fitting the ordinal exposure variables as continuous variables and evaluated using the Wald test.

The covariates included in the multivariate analyses were those found to significantly (*p* \< 0.05) contribute to the multivariate model for colon and/or rectal cancer (age at baseline, sex, body mass index, family history of colorectal cancer, and smoking status) or to influence the RR by more than ten percent, as well as energy intake.

Results {#Sec10}
=======

Lack of expression in MLH1 was observed in 13% (54 out of 428) of tumors from colon cancer patients (Table [1](#Tab1){ref-type="table"}). *APC* truncating mutations were observed in tumors from 32% of colon cancer patients (127 out of 401) and 44% of rectal cancer patients (57 out of 130) (Table [1](#Tab1){ref-type="table"}). C:G→T:A transitions or G:C→T:A transversions that would result in a stop codon were observed in 10% and 5% of colon cancer patients and 12% and 5% of rectal cancer patients, respectively. These figures are similar to the percentages reported for the total group of colon and rectal cancer patients for whom *APC* mutation status was available, but for whom dietary intake data were not always complete \[[@CR25]\]. Table 1Baseline dietary intake and other characteristics of the subcohort and colon and rectum cancer patients from The Netherlands cohort studySubcohortColon cancer (*n *= 428)*p*-value^b^Colon cancer (*n* = 401)*p*-value^b^Rectal cancer (*n* = 130)*p*-value^b^MLH1 expression^a^No MLH1 expression^a^*APC *− ^c^*APC *+^c^*APC *−^c^*APC *+^c^*N*2,948374542741277357    Sex (%men)485641*0.04*5256*0.49*6467*0.79*    Age (years)61.3 ± 4.263.0 ± 4.062.8 ± 4.5*0.91*63.1 ± 4.062.7 ± 4.0*0.34*62.2 ± 4.462.6 ± 3.5*0.63*Fat variables (g/day)^d^    Total fat83.8 ± 15.885.1 ± 14.784.1 ± 17.5*0.57*85.2 ± 15.084.8 ± 14.9*0.80*85.1 ± 14.286.7 ± 14.8*0.52*    Saturated fat33.2 ± 7.533.5 ± 6.633.3 ± 7.6*0.64*33.3 ± 6.733.5 ± 7.0*0.92*33.0 ± 5.835.5 ± 7.7*0.05*    MUFA^e^31.4 ± 7.031.9 ± 6.531.1 ± 7.5*0.45*31.8 ± 6.631.9 ± 6.6*0.98*31.8 ± 6.132.8 ± 6.2*0.37*    PUFA^f^17.3 ± 7.517.9 ± 7.517.4 ± 6.8*0.85*18.2 ± 7.317.8 ± 7.6*0.44*18.6 ± 8.716.5 ± 6.9*0.27*    Linoleic acid16.0 ± 7.516.7 ± 7.516.6 ± 7.0*0.76*17.0 ± 7.416.6 ± 7.7*0.36*17.5 ± 8.815.2 ± 7.2*0.15*    Linolenic acid1.3 ± 0.61.2 ± 0.51.3 ± 0.6*0.98*1.2 ± 0.51.3 ± 0.5*0.57*1.3 ± 0.61.3 ± 0.6*0.79*Other dietary factors    Fibre (g/day)27.0 ± 8.224.5 ± 8.125.2 ± 7.1*0.13*26.7 ± 7.927.9 ± 8.1*0.20*28.1 ± 7.028.2 ± 9.0*0.78*    Alcohol (g/day)^g^10.1 ± 14.111.0 ± 14.810.7 ± 17.0*0.49*11.0 ± 14.911.3 ± 16.5*0.89*12.2 ± 14.914.5 ± 18.1*0.53*    Fruit (g/day)177.0 ± 118.0178.8 ± 122.1160.5 ± 137.7*0.07*169.7 ± 121.9187.5 ± 132.2*0.11*197.4 ± 155.1205.0 ± 118.3*0.21*    Vegetables (g/day)193.8 ± 82.2191.3 ± 82.3185.4 ± 73.8*0.80*187.9 ± 80.7192.7 ± 85.2*0.71*186.3 ± 68.5169.0 ± 122.2*0.69*    Energy (kj/day)8,028 ± 2,1648,080 ± 2,0597,505 ± 1,718*0.07*7,845 ± 1,8998,335 ± 2,306*0.09*8,433 ± 1,9248,449 ± 1,616*0.92*Other characteristics    BMI^h^ (kg/m^2^)25.1 ± 3.125.6 ± 3.225.6 ± 3.5*0.57*25.5 ± 3.2825.8 ± 3.1*0.30*25.3 ± 3.125.1 ± 2.8*0.92*    Family history of CRC^i^ (% yes)6139*0.49*1111*0.98*1011*0.86*Smoker (%)    Never37373336382633    Ex-smoker35453746434739    Current smoker281830*0.12*1819*0.88*2728*0.59*Physical activity (%)^g^    \<30 min/day21212219261726    30-60 min/day32332233282832    60-90 min/day21211922182418    \>90 min/day272537*0.20*2627*0.31*3225*0.43*^a^For rectal cancer there were only two patients without *MLH1* expression, these are not shown separately in this table^b^*p*-value for the difference between cancer patients with and without *MLH1* expression and colon and rectal cancer patients with and without a mutation leading to the introduction of a stop codon in *APC*^c^*APC*−: cancer patients without a mutation in the MCR of the *APC* gene leading to a stop codon; APC + : cancer patients with a mutation in the MCR of the *APC* gene leading to a stop codon^d^Adjusted for energy intake^e^Monounsaturated fat^f^Polyunsaturated fat^g^For alcohol intake and physical activity the mean levels in the subcohort are based on 2,862 and 2,915 subjects respectively. Four and six colon cancer cases had missing values for alcohol intake and physical activity respectively. Two and one rectal cancer case had missing values for alcohol intake and physical activity respectively^h^BMI: body mass index^i^CRC: colorectal cancer

Colon and rectal cancer patients were generally older and more frequently men than subcohort members (Table [1](#Tab1){ref-type="table"}). Colon cancer patients lacking MLH1 expression in their tumor were significantly less often men than patients with expression of the gene (41% vs. 56%). There were no striking differences in fat intake between patients and subcohort members or between patients with or without MLH1 expression or *APC* mutations in their tumors. Only rectal cancer patients with a tumor harboring a truncating *APC* mutation had a higher intake of saturated fat than rectal cancer patients without a truncating *APC* mutation (*p *= 0.05).

Neither total fat nor different types of fat appeared to be associated with overall colon cancer risk in this population (Table [2](#Tab2){ref-type="table"}). For different subgroups of colon cancer based on absence of MLH1 expression or absence or presence of *APC* truncating mutations in their tumors, total fat intake and most of the specific types of fat intake variables were also not associated with risk. However, polyunsaturated fat intake, and especially linoleic acid intake, appeared to be associated with an increased risk of colon tumors without MLH1 expression and with colon tumors without *APC* truncating mutations, but not with colon tumors with *APC* truncating mutations (Table [2](#Tab2){ref-type="table"}). For colon tumors without MLH1 expression, the RR according to the quartiles of linoleic acid intake were increased, though not significantly, for all the categories of intake above the reference (lowest quartile of intake), i.e., 1.66 (95% CI 0.69--3.98), 2.14 (95% CI 0.91--5.00) and 2.02 (95% CI 0.86--4.76) for the second through the fourth quartiles respectively, and the test for linear trend was borderline significant (*p *= 0.08). A similar trend was observed for the risk of colon tumors without *APC* truncating mutations (RR over the quartiles of linoleic acid intake: 1.50 (95% CI 1.02--2.21), 1.68 (95% CI 1.15--2.45) and 1.44 (95% CI 0.99--2.11) respectively, *p*-trend = 0.05 (Table [2](#Tab2){ref-type="table"}). Additional analyses for subgroups of colon tumors with specific truncating point mutations in *APC* did not show any associations with the intake of fat or different types of fat (results not shown). Table 2Adjusted incidence rate ratios and 95% confidence intervals for colon cancer patients overall, without *MLH1* expression, and with and without an *APC* mutation leading to a stop codon, according to the intake of fat variables (The Netherlands Cohort Study)Dietary fat intakeMedian intake (g/day)Person years^b^Colon cancerOverallNo MLH1 expression*APC* --^a^*APC*+^a^MenWomenNumber of patientsRR^c^(95% CI)^c^Number of patientsRR^c^(95% CI)^c^Number of patientsRR^c^(95% CI)^c^Number of patientsRR^c^(95% CI)^c^Total fat    Q178.063.03,5491101.00*(reference)*111.00*(reference)*611.00*(reference)*401.00*(reference)*    Q290.271.43,5561251.09(0.82--1.44)171.47(0.69--3.14)871.34(0.94--1.90)320.80(0.49--1.28)    Q398.577.63,579890.75(0.55--1.01)110.94(0.40--2.17)550.82(0.56--1.21)240.57(0.33--0.96)    Q4108.885.33,5881100.96(0.72--1.28)151.30(0.59--2.86)711.11(0.77--1.59)310.74(0.46--1.20)*    p*-value^d^*0.290.820.710.13*    1SD increment^e^1.00(0.88--1.13)1.21(0.82--1.77)1.04(0.89--1.22)0.93(0.76--1.14)Saturated fat    Q128.923.93,567991.00*(reference)*91.00*(reference)*591.00*(reference)*331.00*(reference)*    Q233.727.83,5501201.20(0.89--1.61)141.48(0.63--3.49)841.38(0.97--1.97)300.94(0.55--1.61)    Q338.330.93,5831151.11(0.82--1.49)191.93(0.86--4.32)731.15(0.79--1.66)331.01(0.60--1.68)    Q445.836.63,5711000.94(0.69--1.27)121.25(0.52--3.00)580.90(0.62--1.32)310.89(0.53--1.48)*    p*-value^d^*0.540.480.350.72*    1SD increment^e^0.97(0.87--1.08)1.12(0.82--1.51)0.95(0.83--1.09)0.95(0.79--1.14)MUFA^f^    Q128.222.43,546981.00*(reference)*111.00*(reference)*561.00*(reference)*311.00*(reference)*    Q233.226.03,5461221.20(0.89--1.61)141.15(0.52--2.53)791.33(0.92--1.91)361.18(0.72--1.95)    Q336.928.93,5801131.12(0.83--1.52)141.15(0.52--2.54)761.30(0.89--1.89)311.03(0.60--1.77)    Q442.533.13,6001010.99(0.73--1.34)151.25(0.58--2.71)631.08(0.74--1.57)290.90(0.54--1.52)*    p*-value^d^*0.790.590.800.57*    1SD increment^e^0.99(0.88--1.12)1.04(0.73--1.46)1.01(0.87--1.17)0.98(0.81--1.18)PUFA^g^    Q111.68.83,507911.00*(reference)*81.00*(reference)*491.00*(reference)*321.00*(reference)*    Q216.012.43,5621181.37(1.02--1.86)162.03(0.86--4.81)731.55(1.06--2.28)331.13(0.68--1.89)    Q320.916.23,6181131.24(0.91--1.68)162.00(0.84--4.76)781.57(1.07--2.31)300.96(0.57--1.62)    Q429.322.53,5801121.21(0.89--1.63)141.75(0.72--4.24)741.47(1.01--2.16)320.98(0.59--1.63)*    p*-value^d^*0.380.260.060.79*    1SD increment^e^1.03(0.94--1.14)1.07(0.82--1.38)1.09(0.97--1.23)1.00(0.84--1.19)Linoleic acid    Q110.07.53,509861.00*(reference)*81.00*(reference)*491.00*(reference)*261.00*(reference)*    Q214.811.23,5861221.49(1.10--2.02)131.66(0.69--3.98)711.50(1.02--2.21)401.65(0.99--2.76)    Q319.514.93,5991121.32(0.97--1.79)172.14(0.91--5.00)821.68(1.15--2.45)251.00(0.57--1.76)    Q428.021.23,5741141.30(0.96--1.77)162.02(0.86--4.76)721.44(0.99--2.11)361.35(0.80--2.28)*    p*-value^d^*0.200.080.050.65*    1SD increment^e^1.06(0.96--1.17)1.15(0.90--1.48)1.12(0.99--1.26)1.02(0.86--1.21)Linolenic acid    Q10.80.63,5181071.00*(reference)*111.00*(reference)*681.00*(reference)*311.00*(reference)*    Q21.20.93,5741040.95(0.70--1.30)171.32(0.60--2.89)720.99(0.68--1.43)240.84(0.47--1.49)    Q31.51.23,5711171.10(0.82--1.48)110.91(0.40--2.10)620.89(0.62--1.29)431.48(0.91--2.40)    Q42.01.63,6041061.01(0.76--1.36)151.32(0.61--2.84)721.08(0.76--1.53)290.97(0.57--1.65)*    p*-value^d^*0.680.730.820.52*    1SD increment^e^0.98(0.89--1.09)1.07(0.79--1.44)0.97(0.85--1.10)1.01(0.86--1.19)^a^*APC*−: cancer patients without a mutation in the MCR of the *APC* gene leading to a stop codon; APC +: cancer patients with a mutation in the MCR of the *APC* gene leading to a stop codon^b^Person years at risk are estimated from the subcohort^c^Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer^d^*p*-value for trend over the quartiles of intake of fat variables^e^For 1 standard deviation of intake of fat in the subcohort (see Table [1](#Tab1){ref-type="table"}); i.e., 15.8 g/day for total fat, 7.5 g/day for saturated fat, 7.0 g/day for monounsaturated fat, 7.5 g/day for polyunsaturated fat, 7.5 g/day for linoleic acid and 0.6 g/day for linolenic acid^f^Monounsaturated fat^g^Polyunsaturated fat

For overall rectal cancer, associations with the intake of total fat or different types of fat were not observed (Table [3](#Tab3){ref-type="table"}). Also after taking account of truncating *APC* mutations in rectal tumors, none of the fat intake variables were significantly associated with risk of rectal cancer. Only the intake of saturated fat appeared to be inversely associated with rectal tumors without *APC* truncating mutations (RR for the highest versus the lowest quartile of intake: 0.46 (95% CI 0.22--0.97), *p*-trend = 0.07) (Table [3](#Tab3){ref-type="table"}). For rectal tumors with specific types of *APC* truncating mutations no associations were observed with any of the fat intake variables (results not shown). Table 3Adjusted incidence rate ratios and 95% confidence intervals for rectal cancer patients overall, and with and without an *APC* mutation leading to a stop codon, according to the intake of fat variables. (The Netherlands Cohort Study)Dietary fat intakeMedian intake (g/day)Person years^b^Rectal cancerOverall*APC* −^a^*APC*+^a^MenWomenNumber of patientsRR^c^(95% CI)^c^Number of patientsRR^c^(95% CI)^c^Number of patientsRR^c^(95% CI)^c^Total fat    Q178.063.03,549431.00*(reference)*241.00*(reference)*151.00*(reference)*    Q290.271.43,556390.89(0.56--1.39)170.70(0.37--1.34)120.79(0.36--1.70)    Q398.577.63,579330.74(0.46--1.19)160.65(0.33--1.26)140.91(0.43--1.90)    Q4108.885.33,588380.87(0.55--1.36)150.60(0.31--1.16)161.06(0.51--2.19)*    p*-value^d^*0.420.130.80*    1SD increment^e^0.91(0.76--1.09)0.84(0.65--1.08)0.94(0.69--1.28)Saturated fat    Q128.923.93,567431.00*(reference)*231.00*(reference)*141.00*(reference)*    Q233.727.83,550340.80(0.49--1.29)180.81(0.42--1.56)120.87(0.39--1.91)    Q338.330.93,583441.02(0.66--1.59)210.92(0.49--1.73)120.86(0.40--1.88)    Q445.836.63,571330.74(0.46--1.18)110.46(0.22--0.97)191.30(0.65--2.63)*    p*-value^d^*0.380.070.47*    1SD increment^e^0.95(0.81--1.12)0.81(0.65--1.02)1.16(0.89--1.50)MUFA^f^    Q128.222.43,546441.00*(reference)*231.00*(reference)*151.00*(reference)*    Q233.226.03,546310.70(0.44--1.13)180.79(0.41--1.49)90.62(0.27--1.43)    Q336.928.93,580400.91(0.58--1.44)150.67(0.34--1.33)201.36(0.67--2.78)    Q442.533.13,600390.88(0.56--1.37)170.72(0.38--1.36)130.88(0.40--1.90)*    p*-value^d^*0.820.280.76*    1SD increment^e^0.94(0.78--1.12)0.85(0.67--1.08)1.00(0.76--1.33)PUFA^g^    Q111.68.83,507451.00*(reference)*171.00*(reference)*211.00*(reference)*    Q216.012.43,562320.74(0.46--1.18)191.17(0.60--2.28)100.49(0.23--1.07)    Q320.916.23,618390.86(0.55--1.34)160.94(0.47--1.88)160.76(0.39--1.48)    Q429.322.53,580380.82(0.53--1.29)211.20(0.63--2.29)100.47(0.22--1.00)*    p*-value^d^*0.530.730.11*    1SD increment^e^0.98(0.83--1.16)1.06(0.84--1.34)0.78(0.60--1.03)Linoleic acid    Q110.07.53,509391.00*(reference)*181.00*(reference)*181.00*(reference)*    Q214.811.23,586391.03(0.65--1.64)170.98(0.50--1.92)140.80(0.40--1.63)    Q319.514.93,599350.90(0.56--1.44)160.90(0.45--1.79)150.84(0.42--1.68)    Q428.021.23,574411.03(0.65--1.62)221.19(0.63--2.24)100.54(0.25--1.18)*    p*-value^d^*0.950.650.15*    1SD increment^e^0.99(0.84--1.17)1.09(0.86--1.38)0.79(0.60--1.04)Linolenic acid    Q10.80.63,518421.00*(reference)*181.00*(reference)*181.00*(reference)*    Q21.20.93,574380.92(0.57--1.48)201.16(0.58--2.31)100.55(0.25--1.24)    Q31.51.23,571360.87(0.55--1.38)150.87(0.43--1.75)130.72(0.35--1.48)    Q42.01.63604380.92(0.58--1.44)201.13(0.60--2.14)160.90(0.45--1.80)*    p*-value^d^*0.680.930.91*    1SD increment^e^0.95(0.81--1.12)0.98(0.77--1.24)1.03(0.81--1.31)^a^*APC*−: cancer patients without a mutation in the MCR of the *APC* gene leading to a stop codon; APC +: cancer patients with a mutation in the MCR of the *APC* gene leading to a stop codon^b^Person years at risk are estimated from the subcohort^c^Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer^d^*p*-value for trend over the quartiles of intake of fat variables^e^For 1 standard deviation of intake of fat in the subcohort (see Table [1](#Tab1){ref-type="table"}); i.e., 15.8 g/day for total fat, 7.5 g/day for saturated fat, 7.0 g/day for monounsaturated fat, 7.5 g/day for polyunsaturated fat, 7.5 g/day for linoleic acid and 0.6 g/day for linolenic acid^f^Monounsaturated fat^g^Polyunsaturated fat

Additional analyses were conducted to assess whether the observed associations of polyunsaturated fat intake, and especially linoleic acid intake, with the increased risk of colon tumors lacking MLH1 expression and with the increased risk of colon tumors without *APC* truncating mutations, were observed because of an underlying association with colon tumors harboring a *KRAS* mutation, as previously observed \[[@CR22]\]. Excluding tumors with a *KRAS* mutation resulted in the absence of a statistically significant association of polyunsaturated fat intake and linoleic acid intake with colon tumors lacking MLH1 expression (*p*-trend = 0.34 and 0.12, respectively) and those lacking *APC* tuncating mutations (*p*-trend = 0.77 and 0.99, respectively). Intake of polyunsaturated fat or linoleic acid was neither associated with the risk of colon cancer without any of the three gene defects, nor with the risk of colon cancer only lacking MLH1 expression, nor with the risk of colon cancer with only truncating *APC* mutations (Table [4](#Tab4){ref-type="table"}). With increasing intake of polyunsaturated fat and of linoleic acid, a strongly increased risk of colon cancer with only activating *KRAS* mutations was observed (Table [4](#Tab4){ref-type="table"}) (*p*-trend ≤ 0.001 for both polyunsaturated fat and linoleic acid intake). The RRs for one standard deviation increase in intake were 1.40 (95% CI 1.17--1.68) and 1.41 (95% CI 1.18--1.69), respectively. The RRs for polyunsaturated fat (not shown) and linoleic acid intake were of similar size when estimated separately for men (1.41, 95% CI 1.15--1.72 for 1 standard deviation increase in linoleic acid intake) and women (1.42, 95% CI 0.96--2.10), and were elevated for proximal (1.23, 95% CI 0.99--1.53) and distal colon cancer (1.53, 95% CI 1.21--1.95). Likewise, a positive association was observed for all colorectal cancers (1.24, 95% CI 1.06--1.47 and *p*-trend = 0.01), based on a total of 87 cases (i.e., including the rectosigmoid). Table 4Adjusted incidence rate ratios and 95% confidence intervals for colon cancer patients without any of the gene defects or with only a single gene defect, i.e., either lack of MLH1 expression, a truncating *APC* gene mutation or an activating *KRAS* gene mutation, according to the intake of polyunsaturated fat and linoleic acid intake (The Netherlands Cohort Study)Dietary fat intakePerson years^e^Colon cancerNo gene defects^a^Only lack of MLH1 expression^b^Only truncating *APC* mutations^c^Only activating *KRAS* mutations^d^Number of patientsRR^f^(95% CI)^f^Number of patientsRR^f^(95% CI)^f^Number of patientsRR^f^(95% CI)^f^Number of patientsRR^f^(95% CI)^f^PUFA^g^Q13,507391.00*(reference)*61.00*(reference)*181.00*(reference)*41.00*(reference)*Q23,562441.15(0.73--1.81)142.48(0.94--6.54)211.31(0.68--2.53)143.76(1.21--11.69)Q33,618451.10(0.70--1.73)111.89(0.69--5.16)150.86(0.43--1.74)195.00(1.67--14.99)Q43,580350.86(0.54--1.38)101.72(0.61--4.81)130.70(0.34--1.45)286.74(2.36--19.51)*p*-value^h^*0.510.480.19≤0.001*1SD increment^i^0.96(0.82--1.13)1.01(0.72--1.40)0.90(0.71--1.14)1.40(1.17--1.68)Linoleic acidQ13,509381.00*(reference)*71.00*(reference)*141.00*(reference)*41.00*(reference)*Q23,586451.20(0.77--1.90)101.51(0.58--0.93)262.03(1.03--3.99)154.06(1.32--12.46)Q33,599451.15(0.73--1.81)142.08(0.84--5.19)130.99(0.46--2.13)215.61(1.88--16.68)Q43,574350.90(0.56--1.44)101.49(0.56--3.97)140.97(0.46--2.06)256.02(2.09--17.41)*p*-value^h^*0.620.300.38≤0.001*1SD increment^i^0.98(0.84--1.15)1.08(0.79--1.49)0.91(0.73--1.14)1.41(1.18--1.69)^a^Colon cancer patients with MLH1 expression and without truncating *APC* or activating *KRAS* gene mutations^b^Colon cancer patients lacking MLH1 expression but without truncating *APC* or activating *KRAS* gene mutations^c^Colon cancer patients with a truncating *APC* gene mutation but with MLH1 expression and without activating *KRAS* gene mutations^d^Colon cancer patients with an activating *KRAS* gene mutations but with MLH1 expression and without truncating *APC* gene mutations^e^Person years at risk are estimated from the subcohort.^f^Incidence rate ratios (RR) and 95% confidence intervals (95% CI) are adjusted for age, sex, body mass index, smoking, energy intake and family history of colorectal cancer.^g^Polyunsaturated fat^h^*p*-value for trend over the quartiles of intake of fat variables^i^For 1standard deviation if intake of fat in the subcohort (see Table [1](#Tab1){ref-type="table"}); i.e., 7.5 g/day for polyunsaturated fat and 7.5 g/day for linoleic acid

Likewise, additional analyses were conducted for saturated fat intake in relation to risk of rectal cancer without *APC* truncating mutations, also excluding individuals with a *KRAS* mutation and lack of MLH1 expression. The association did not change substantially. Again, only the highest level of intake showed a significant reduced risk of cancer compared to the reference category (RR 0.40 95% CI 0.14--1.15, *p*-trend = 0.09).

Discussion {#Sec11}
==========

In this prospective study, we observed that the intake of total, saturated and monounsaturated fat was not associated with the risk of colon cancer, rectal cancer, or the different molecular subgroups of cancer based on lack of MLH1 expression or truncating mutations in the *APC* gene. This was also found for polyunsaturated fat intake and rectal cancer. However, linoleic acid showed an association with increased risk of colon tumors with only an activated *KRAS* mutation and no additional truncating *APC* mutation or lack of MLH1 expression.

None of the other epidemiological studies report on specific fatty acids and the risk of molecular surrogate end-points for colon or rectal cancer or adenomas \[[@CR35]--[@CR43]\]. Some of these studies report on various types of fat depending on saturation level, but the results are inconsistent across the studies \[[@CR35], [@CR38], [@CR41], [@CR42]\] including the current study.

Diergaarde et al. observed unsaturated fat intake to be associated with increased colon carcinomas with a truncating *APC* mutation \[[@CR38]\]. No distinction was made between mono- and polyunsaturated fats. In our study, we did not observe any association between various types of fat intake and risk of colon or rectal cancer with or without truncating *APC* mutations after patients also harboring a *KRAS* mutation in their tumor were excluded from the analyses. We observed a possible inverse association between saturated fat intake and risk of rectal tumors without a truncating *APC* mutation. However, the association was weak, did not increase gradually according to the quartiles of intake and was only a result of the reduced risk in the highest category of intake. Furthermore, in absence of a biological explanation for this finding and considering the large number of associations investigated, the observation may best be attributed to chance.

Slattery et al. observed saturated and monounsaturated fats, but not polyunsaturated fat, to be associated with increased risk of colon tumors with specific *KRAS* mutations, i.e., a G→T transversion at codon 12 \[[@CR41]\]. No distinction was made between ω-6 and ω-3 fatty acids. We observed an association between polyunsaturated fat intake, especially linoleic acid, and increased risk of colon tumors with a *KRAS* mutation, regardless of the type of mutations \[[@CR22]\].

Finally, Bautista et al. observed an inverse association between monounsaturated fats, mostly derived from olive oil in the Spanish diet, and risk of colon cancer without *KRAS* mutations \[[@CR35]\]. Since olive oil was rarely consumed by this elderly Dutch population in the years preceding 1986 (the cohort baseline), this could explain the lack of association for this type of fat in our study. However, a recent Dutch case--control study on risk factors for colorectal adenomas showed a significant positive association between monounsaturated fats and adenoma risk \[[@CR42]\].

Several factors hamper comparisons between our findings and those of other epidemiological studies and may in part explain observed inconsistencies. First, our study is the first large prospective cohort study incorporating molecular end-points for colon and rectal cancer. One of the other studies was a cross-sectional case--case comparison study \[[@CR40]\], and the others were case--control studies of varying size (ranging from 108 to 1,510 cases) \[[@CR35]--[@CR39], [@CR41]--[@CR43]\]. Second, varying end-points were considered. Three of the other studies focused on adenomas instead of carcinomas \[[@CR37], [@CR40], [@CR42]\], and three studies also incorporated rectal tumors but did not distinguish between colon and rectum \[[@CR35], [@CR37], [@CR42]\].

Previously, we reported the association between linoleic acid intake and increased risk of colon tumors with *KRAS* mutations (adjusted RR for one standard deviation of increase 1.22 (95% CI 1.05--1.42)) \[[@CR22]\]. Now, we report that the association appears to be confined to those colon tumors with activating *KRAS* mutations and an otherwise intact *APC* gene and with MLH1 expression. In addition, the association appears to be robust since RRs clearly increase over the quartiles of linoleic acid intake and the RRs for one standard deviation increase in linoleic acid intake are similar for men and women, and is increased for proximal and distal colon cancer as well as for overall colorectal cancer, including the rectosigmoid. The activating *KRAS* mutations at codons 12 and 13 are predominantly G→T and G→A mutations \[[@CR27]\] which could be a result of MDA DNA adduct formation \[[@CR18], [@CR19]\] associated with increased ω-6 polyunsaturated fat intake \[[@CR21]\]. Therefore, even though chance cannot be ruled out and verification by others is warranted, the association seems quite plausible.

Still several issues remain puzzling. First, why is the observed association for linoleic acid confined to colon cancer and not rectum cancer with only a *KRAS* mutation? The multistep model for molecular aberrations underlying colorectal carcinogenesis is likely to apply equally for both tumor subsites \[[@CR7], [@CR8], [@CR15]\]. However, lack of MLH1 expression in our study is rare among rectum cancer patients and there is growing evidence for differences in the etiology of colon and rectal tumors \[[@CR33]\].

Second, why is the association with linoleic acid observed for *KRAS* and not for truncating *APC* gene mutations? It is unlikely that adduct formation selectively occurs in one gene but not in the other. However, *KRAS* is an oncogene requiring only one mutation for the gene to be activated, whereas APC is a tumor suppressor gene requiring an additional aberration in the other allele for loss of function. In addition, more than half of the patients with an *APC* mutation had multiple mutations in this gene \[[@CR25]\], complicating data analyses and interpretation. Additional analyses for subgroups of colon tumors with specific truncating point mutations in *APC* did not show any associations with the intake of fat or different types of fat.

This still does not satisfy our third query, i.e., why are the associations specifically confined to this subgroup of colon cancer patients whose tumors are characterized by activating *KRAS* mutations, and not truncating *APC* mutations or lack of MLH1 expression? It is speculative, but plausible, that when *KRAS* is the only one of the three genes affected, the mutation may more likely be the result of exogenous exposure, for example a relatively high linoleic acid intake. In contrast, when a *KRAS* mutation co-occurs with a mutation in *APC* or, although more rarely, in addition to a defective MLH1, these other early gene defects also had a role in tumor formation and may have resulted in a mutator phenotype leading to mutations in other genes (such as the *KRAS* gene) irrespective of exogenous factors. Since there is no information on the timing of genetic aberrations in this type of human studies, we cannot verify this with our data. Aberrations in other genes, not available for this study, but possibly involved in early tumorigenesis of colorectal cancer, could not be accounted for in analyses and may have influenced results. However, a recent systematic sequence analysis of 13,023 exons in individual colorectal cancers showed that the prevalence of mutations other than in *APC*, *KRAS* and *TP53* is rather low \[[@CR44]\], and mutations in *TP53* is not an early event in colorectal carcinogenesis. Finally, results are based on relatively small numbers of patients, especially in the reference group of polyunsaturated fat or linoleic acid intake (four patients, see Table [4](#Tab4){ref-type="table"}), and point estimates of RRs for quartiles of intake of polyunstaturated fat or linoleic acid should therefore, be interpreted cautiously. Nevertheless, as discussed previously, the association appears to be robust when regarding the results for one standard deviation increase in linoleic acid intake (based on a total of 65 patients). Therefore, Breivik and Glaudernack's hypothesis for distinct carcinogens to exert their effect on two proposed types of genetic instability, i.e., microsatellite instability and chromosomal instability \[[@CR16]\], may be extended to the potential effect of carcinogens on more specific genetic pathways to colorectal tumorigenesis, as for example the *KRAS* mutated pathway.

The data from this large prospective cohort study suggest that linoleic acid intake is strongly associated with colon tumors with an aberrant *KRAS* gene, but an intact *APC* gene and MLH1 expression. Verification in other studies is warranted. Possibly, tumors revealing the involvement of distinct genetic pathways on the basis of specific genetic aberrations, may have a unique etiology.
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